Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - thelancet.com
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
AC Ong, O Devuyst, B Knebelmann, G Walz - Lancet (London, England), 2015 - sonar.ch
English Autosomal dominant polycystic kidney disease is the most common inherited kidney
disease and accounts for 7-10% of all patients on renal replacement therapy worldwide …
disease and accounts for 7-10% of all patients on renal replacement therapy worldwide …
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
AC Ong, O Devuyst, B Knebelmann… - Lancet (London …, 2015 - europepmc.org
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - infona.pl
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
A Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - dial.uclouvain.be
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
[引用][C] Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - cir.nii.ac.jp
Autosomal dominant polycystic kidney disease: the changing face of clinical management |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …
Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann… - Lancet (London …, 2015 - pubmed.ncbi.nlm.nih.gov
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
Autosomal dominant polycystic kidney disease: the changing face of clinical management.
AC Ong, O Devuyst, B Knebelmann… - Lancet (London, England …, 2015 - folia.unifr.ch
English Autosomal dominant polycystic kidney disease is the most common inherited kidney
disease and accounts for 7-10% of all patients on renal replacement therapy worldwide …
disease and accounts for 7-10% of all patients on renal replacement therapy worldwide …
Autosomal dominant polycystic kidney disease: the changing face of clinical management
A Ong, O Devuyst, B Knebelmann, G Walz - Lancet, 2015 - zora.uzh.ch
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although …
Autosomal dominant polycystic kidney disease: the changing face of clinical management
ACM Ong, O Devuyst, B Knebelmann, G Walz - The Lancet, 2015 - thelancet.com
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …
and accounts for 7–10% of all patients on renal replacement therapy worldwide. Although …